AngioDynamics, Inc. ANGO
As ofNov 20, 2026, 12:29 PM EST
- YTD
- -15.81%
- 1 year
- -5.26%
- Market cap
- 454.19M
- Revenue (ttm)
- 292.73M
- Profit margin
- -83.02%
- EPS (ttm)
- -0.78
- Shares out
- 40.63M
- Forward P/E
- -36.21
- YTD return
- -15.81%
- 1-year return
- -5.26%
- 50-day average
- 7.35
- Volume
- 112.94K
- Avg volume
- 646.78K
- Open
- 10.87
- Previous close
- 10.76
- Day's range
- 10.79 – 10.87
- 52-week range
- 9.39 – 16.29
- Beta
- 0.67
- Analysts
- Strong Buy
- Price target
- 13.00 (+20.3%)
Key statistics
- 200-day average
- 6.77
- Enterprise value
- 311.65M
- Price / sales
- 1.21
- Price / book
- 1.81
- Revenue growth
- -14.20%
- Free cash flow
- 24.19M
- Total cash
- 55.01M
- Total debt
- 5.42M
- Return on equity
- -77.85%
- Short % of float
- 3.42%
Fundamental scorecard
7 of 25 checks passed on ANGO’s reported financials
7of 25 checks passed
- Value 1 of 5
- Growth 1 of 5
- Profitability 1 of 5
- Financial health 4 of 5
- Dividend 0 of 5
Statements to Aug 31, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 8, 2025 | Nov 1, 2024 | -0.11 | — | — | — |
| Oct 3, 2024 | Aug 1, 2024 | -0.15 | -0.11 | +0.04 | +26.67% |
| Jul 16, 2024 | May 1, 2024 | -0.20 | -0.06 | +0.14 | +70.00% |
| Apr 4, 2024 | Feb 1, 2024 | -0.14 | -0.16 | -0.02 | -14.29% |
| Jan 5, 2024 | Nov 1, 2023 | -0.09 | -0.05 | +0.04 | +44.44% |
| Oct 4, 2023 | Aug 1, 2023 | -0.14 | -0.12 | +0.02 | +14.29% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 10, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 4, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 4, 2024 | Canaccord Genuity | main | Buy | Buy |
| Sep 20, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jul 17, 2024 | Canaccord Genuity | main | Buy | Buy |
| Jul 17, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About AngioDynamics, Inc.
AngioDynamics, Inc., a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium. Its thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac venous drainage cannula and extracorporeal circuit, indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. The company also offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters, and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. In addition, it provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro-Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. The company was founded in 1988 and is headquartered in Latham, New York.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- United States
- Website
- angiodynamics.com
News
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now
12 Health Care Stocks Moving In Monday's Pre-Market Session AngioDynamics Reports DIRECT Study Findings Showing Longer Overall Survival In Stage III Pancreatic Ductal Adenocarcinoma, Gets Category I CPT Code For Open IRE Ablation Of Pancreatic Tumors, Effective January 1, 2027
Your note
Sign in to keep a note on ANGO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AUEN EILEEN O SHEA | Director | Stock Award(Grant) | Jul 16, 2024 | 87,043 |
| CAMPBELL CHAD THOMAS | Officer | Stock Award(Grant) | Jul 16, 2024 | 65,366 |
| CLEMMER JAMES C | Chief Executive Officer | Purchase | Oct 6, 2024 | 681,582 |
| DONNELLY HOWARD W | Director | Stock Award(Grant) | Jul 16, 2024 | 149,376 |
| JOHNSON WESLEY E JR | Director | Stock Award(Grant) | Jul 16, 2024 | 125,863 |
| LAWRENCE WEISS T | Officer | Stock Award(Grant) | Dec 1, 2024 | 52,697 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 11.47% | 4,660,419 | 40.50M | Sep 29, 2024 |
| Systematic Financial Management, L.P. | 5.93% | 2,410,346 | 20.95M | Sep 29, 2024 |
| Vanguard Group Inc | 5.64% | 2,289,855 | 19.90M | Sep 29, 2024 |
| Millennium Management Llc | 5.50% | 2,235,452 | 19.43M | Sep 29, 2024 |
| Dimensional Fund Advisors LP | 3.33% | 1,353,660 | 11.76M | Sep 29, 2024 |
| Renaissance Technologies, LLC | 2.60% | 1,056,814 | 9.18M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.95% | 1,198,947 | 10.42M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.43% | 985,547 | 8.56M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.62% | 659,958 | 5.74M | Sep 29, 2024 |
| Royce Small-Cap Opportunity Fund | 1.40% | 569,410 | 4.95M | Sep 29, 2024 |
| College Retirement Equities Fund-Stock Account | 1.15% | 467,180 | 4.06M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.96% | 389,309 | 3.38M | Aug 30, 2024 |
